RELMADA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant.
| Dated: March 19, 2026 | RELMADA THERAPEUTICS, INC. | |
|---|---|---|
| By: | /s/ Sergio Traversa | |
| Sergio Traversa | ||
| Chief Executive Officer | ||
| (Duly Authorized Officer and Principal Executive Officer) | ||
| By: | /s/ Maged Shenouda | |
| Maged Shenouda | ||
| Chief Financial Officer (Duly Authorized Officer and (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Sergio Traversa | Chief Executive Officer, and Director | March 19, 2026 |
| Sergio Traversa | ||
| /s/ Maged Shenouda | Chief Financial Officer | March 19, 2026 |
| Maged Shenouda | ||
| /s/ Charles J. Casamento | Chairman of the Board | March 19, 2026 |
| Charles J. Casamento | ||
| /s/ Paul Kelly | Chief Operating Officer, and Director | March 19, 2026 |
| Paul Kelly | ||
| /s/ John Glasspool | Director | March 19, 2026 |
| John Glasspool | ||
| /s/ Fabiana Fedeli | Director | March 19, 2026 |
| Fabiana Fedeli | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.